Digistain

AI-powered breast cancer biomarker analytics to reduce unnecessary chemotherapy.

Pre-seed / SeedLondon, UKFounded 2016

About

Digistain uses infrared spectral analysis and AI to provide a personalized risk score that guides oncologists in selecting individualized breast cancer treatment plans. In a government-commissioned study, the technology demonstrated clinical evidence on par with market leaders at a fraction of the cost, potentially reducing unnecessary chemotherapy prescriptions by 30%. The MHRA-cleared tool is expanding globally.

Total Funding

Undisclosed

Key Product

Digistain breast cancer biomarker analytics

Geography

Europe